Signaturefd LLC trimmed its stake in shares of Bristol-Myers Squibb (NYSE:BMY – Free Report) by 7.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 91,375 shares of the biopharmaceutical company’s stock after selling 7,231 shares during the quarter. Signaturefd LLC’s holdings in Bristol-Myers Squibb were worth $3,795,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also modified their holdings of the stock. Northwest Financial Advisors acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at $27,000. ESL Trust Services LLC purchased a new position in Bristol-Myers Squibb during the first quarter worth about $27,000. Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb in the fourth quarter valued at about $34,000. MFA Wealth Advisors LLC acquired a new stake in Bristol-Myers Squibb in the second quarter valued at $39,000. Finally, Fairman Group LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter worth $42,000. Institutional investors and hedge funds own 76.41% of the company’s stock.
Bristol-Myers Squibb Trading Up 0.5 %
NYSE BMY traded up $0.23 during mid-day trading on Friday, reaching $49.95. 9,434,419 shares of the stock were exchanged, compared to its average volume of 15,441,344. The business’s fifty day simple moving average is $45.01 and its 200 day simple moving average is $46.59. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16. The stock has a market capitalization of $101.25 billion, a PE ratio of -16.11, a PEG ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.03.
Bristol-Myers Squibb Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Investors of record on Friday, July 5th were given a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 4.80%. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on BMY. Barclays increased their price target on shares of Bristol-Myers Squibb from $41.00 to $42.00 and gave the company an “underweight” rating in a report on Thursday, August 22nd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Jefferies Financial Group upped their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a report on Wednesday. TD Cowen boosted their target price on Bristol-Myers Squibb from $45.00 to $53.00 and gave the stock a “hold” rating in a research report on Monday, August 12th. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 29th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $54.67.
Read Our Latest Stock Analysis on Bristol-Myers Squibb
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.
See Also
- Five stocks we like better than Bristol-Myers Squibb
- How to Most Effectively Use the MarketBeat Earnings Screener
- The Solar Stock Battle: Is Daqo or JinkoSolar Your Next Big Win?
- How to Start Investing in Real Estate
- Are These Chinese Stocks a Buy? Michael Burry’s Top Picks Say Yes
- Insider Buying Explained: What Investors Need to Know
- Five Below Stock Faces Challenges Despite Strong Revenue Growth
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.